Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 17/20 | 0.42 |
| ▸ | HTR7 | P34969 | 17/20 | 0.42 |
| ▸ | DRD2 | P14416 | 16/20 | 0.42 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4532829 | 0.99 | HTR1A (0.42) | HTR1AHTR7DRD2HTR6DRD1 | |
| SCHEMBL4537443 | 0.92 | HTR1A (0.41) | HTR1AHTR7DRD2HTR6DRD1 | |
| Hydrochloric Acid SCHEMBL4528497 | 0.91 | HTR1A (0.41) | HTR1AHTR7DRD2HTR6DRD1 | |
| SCHEMBL4537694 | 0.86 | HTR1A (0.42) | HTR1AHTR7DRD2HTR6DRD1 | |
| SCHEMBL4517476 | 0.85 | HTR1A (0.41) | HTR1AHTR7DRD2HTR6DRD1 | |
| Hydrochloric Acid SCHEMBL4528897 | 0.85 | HTR1A (0.43) | HTR1AHTR7DRD2HTR6DRD1 | |
| Hydrochloric Acid SCHEMBL4514047 | 0.84 | HTR1A (0.41) | HTR1AHTR7DRD2HTR6DRD1 | |
| SCHEMBL4517551 | 0.84 | HTR1A (0.41) | HTR1AHTR7DRD2HTR6DRD1 | |
| Phosphoric Acid SCHEMBL5301610 | 0.83 | HTR1A (0.40) | HTR1AHTR7DRD2HTR6DRD1 | |
| Phosphoric Acid SCHEMBL5330436 | 0.82 | HTR1A (0.39) | HTR1AHTR7DRD2HTR6DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312344-A1 | ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-12-17 | — | — | US | claimed |
| US-20090312344-A1 | ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-12-17 | — | — | US | disclosed |
| EP-1758583-A2 | ARYLPIPERAZINE DERIVATIVES USEFUL AS ADRENERGIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005118537-A2 | ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312344-A1 | ARYLPIPERAZINE DERIVATIVES AS ADRENERGIC RECEPTOR ANTAGONISTS | ADRA1D, ADRB1, ADRA1A | HTR1A 16/4885HTR7 125/4885DRD2 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.